HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals.
about
Visceral Leishmaniasis and HIV coinfection in East AfricaLeishmaniasis-HIV coinfection: current challengesDiagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Visceral leishmaniasis and HIV coinfection in the Mediterranean region.Visceral leishmaniasis and HIV coinfection in Latin AmericaL-Asparaginase as a new molecular target against leishmaniasis: insights into the mechanism of action and structure-based inhibitor design.Relapse of visceral leishmaniasis in an HIV-infected patient successfully treated with a combination of miltefosine and amphotericin BDrug resistance in leishmaniasis: Newer developments.Chemotherapy of leishmaniasis: present challenges.Oral effectiveness of PMIC4, a novel hydroxyethylpiperazine analogue, in Leishmania amazonensisLeishmania and other intracellular pathogens: selectivity, drug distribution and PK-PD.Human Competence to Transmit Leishmania infantum to Lutzomyia longipalpis and the Influence of Human Immunodeficiency Virus Infection.Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.A continuous-flow mass biosensor for the real-time dynamic analysis of protease inhibition.Visceral leishmaniasis and HIV coinfection: current perspectives
P2860
Q24290704-6FF3331D-746D-4B3E-86D4-F324EAC93E13Q28078359-B2DC0653-61B3-4ADB-A6FF-BEFBD7D96F4EQ30275257-4E5491FD-BBCD-4297-A6D8-B3A91F2390E0Q34075119-A52F58DE-8AB3-44E4-8042-8EB50EF99A2FQ34214794-21B2D4CD-B506-45D8-943B-3720977C24C3Q35609857-A7E4F688-6B92-446E-BAA9-F040A6240F1FQ36407512-9917CDAF-FB1D-41F2-B417-0CDB9237A525Q37712190-15D42041-40C1-41F4-8BC3-712FAB62D368Q39011875-A0FDDB73-E654-4307-8730-A9FCACD7C29FQ41595098-49EB8DFA-61F6-4A6E-8164-629552B9002FQ41990715-C7ABADCC-F08A-433D-A46E-CCC9609E5501Q45324810-F7BBCD8C-5C7F-4913-9C7C-585EAF664C8DQ47548487-489B9C04-F6FB-4E4B-B1E6-1728E58C6CB3Q53576566-B9B96600-FB3C-442B-A5C4-EFC511B76E2FQ58562873-AF66234B-F993-41ED-8FA2-1CA8B5CCEEE1
P2860
HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
HIV-1 protease inhibitors for ...... n HIV-co-infected individuals.
@en
type
label
HIV-1 protease inhibitors for ...... n HIV-co-infected individuals.
@en
prefLabel
HIV-1 protease inhibitors for ...... n HIV-co-infected individuals.
@en
P2093
P50
P1476
HIV-1 protease inhibitors for ...... n HIV-co-infected individuals.
@en
P2093
Ed Zijlstra
Ermias Diro
Jean-Claude Dujardin
Lutgarde Lynen
Rogelio Lopez-Velez
P304
P356
10.1016/S1473-3099(12)70348-1
P577
2013-03-01T00:00:00Z